Nitto Denko Avecia
Milford, MA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
80.3
Signal Score
✓ FDA Inspections (4)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
✓ HC GMP (6)
Quick Facts: Nitto Denko Avecia
- Signal Score
- 80.3/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Bonus: 3 consecutive NAI inspections
- Headquarters
- Milford, MA
- Modalities
- Oligonucleotide, mRNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Nitto Denko Avecia
Major oligonucleotide CDMO. Capacity expansion underway.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Bonus: 3 consecutive NAI inspections
Sources: FDA Data Dashboard
Bonus: 3 consecutive NAI inspections
FDA Inspections4 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-08-12)
Most Recent HC OutcomeCompliant · 2023-09-18
HC Attribution6 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Bonus: 3 consecutive NAI inspections
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
68.0
Parent company: Nitto Denko (6988.T)
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Nitto Denko (6988.T)
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: Milford, MA
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Sites: Milford, MA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Milford, MA
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Nitto Denko Avecia FDA Inspection History
2026-08
2025-07
2024-08
2023-02
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-08-12 |
Nitto Denko Avecia Inc.
Milford, Massachusetts
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2025-07-25 |
Nitto Avecia Pharma Services, Inc.
Irvine, California
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2024-08-20 |
Nitto Denko Avecia, Inc
Cincinnati, Ohio
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2023-02-08 |
Nitto Denko Avecia Inc.
Milford, Massachusetts
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
general (non-sterile) · 1 site
- Milford, United States · Nitto Denko Avecia Inc. — general (non-sterile) · valid to Jun 29, 2030
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity Beta
From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No open roles were listed at this business's sites on Nov 20, 2026.
Coverage: read from the parent company's careers board and kept only postings at this business's sites (Avecia postings on the Nitto group board (Avecia named in the URL, or the Milford/Cincinnati sites)). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
careers.nitto.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Frequently Asked Questions About Nitto Denko Avecia
How many FDA inspections does Nitto Denko Avecia have on record?
CDMO Signal tracks 4 FDA inspections for Nitto Denko Avecia, sourced from the FDA inspection database. See the full inspection history above.
Has Nitto Denko Avecia received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Nitto Denko Avecia.
What is Nitto Denko Avecia's CDMO Signal Score?
Nitto Denko Avecia has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Nitto Denko Avecia for a manufacturing program?
Use the free AI matchmaker to compare Nitto Denko Avecia against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.5
mRNA, Oligonucleotide, Biologics
TriLink BioTechnologies
San Diego, CA
Signal Score: 63.0
mRNA, Oligonucleotide
RiboBio
Guangzhou, China
Signal Score: 59.0
Oligonucleotide, mRNA
Compare Nitto Denko Avecia with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.